Epigenetics Diagnostics Market To Reach $39.15 Billion By 2030

Epigenetics Diagnostics Market Growth & Trends

The global epigenetics diagnostics market is anticipated to reach USD 39.15 billion by 2030 and is anticipated to expand at a CAGR of 15.5% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth is attributed to increased investment, funding, and approvals for epigenetics research and development, and the increasing prevalence of MDD (Major Depressive Disorder). According to the World Health Organization (WHO), in 2023, approximately 5% of adults experienced depressive disorders. Furthermore, a study published by the National Center for Biotechnology Information (NCBI) in 2022 reported that around 280 million people worldwide are affected by MDD. Epigenetics' applications in drug discovery and development are growing, and genome sequencing is becoming more affordable. Additionally, advancements in technology related to epigenetic drug discovery contribute to this growth.

Additionally, an increase in investment from both public and private organizations in epigenetics is expected to drive market growth from 2023 to 2030. In February 2025, TruDiagnostic introduced the grant, which provides USD 400,000 in funding to support researchers working in DNA methylation, longevity science, and diagnostic innovation. A study published by NCBI in 2022 stated that epigenetic modification plays a crucial role in maintaining cellular homeostasis and the genome and provides information about the cause and development of virus infection.

 Request a free sample copy or view report summary: Epigenetics Diagnostics Market Report

Epigenetics Diagnostics Market Report Highlights

• Reagents dominated the product segment with more than 30.0% share in 2024, owing to their high usage in epigenetic research studies.

• The DNA Methylation segment is expected to grow at the fastest CAGR of 44.5% over the forecast period 2025 – 2030.

• The oncology segment held the largest market share in 2024, and with the increasing incidence of cancer, the epigenetic market is expected to grow over the forecast period.

• The academic research segment held the largest market share in 2024. The growth is attributed to the factors such as increased funding for research and development by various companies and supportive initiatives from the government.

• North America led the epigenetic diagnostics market in 2024 due to the presence of key market players and an advanced healthcare infrastructure. Additionally, increasing awareness along with significant R&D expenditure is expected to fuel growth throughout the forecast period.

Epigenetics Diagnostics Market Segmentation

Grand View Research has segmented the global epigenetics diagnostics market on the basis of product, technology, application, end-use, and region:

Epigenetics Diagnostics Product Outlook (Revenue, USD Million, 2018 - 2030)

• Reagents

• Kits

  • Chip Sequencing Kit

  • Whole Genomic Amplification kit

  • Bisulfite Conversion kit

  • RNA Sequencing kit

• Instruments

• Enzymes

• Service

Epigenetics Diagnostics Application Outlook (Revenue, USD Million, 2018 - 2030)

• Oncology

  • Solid Tumors

  • Others

• Non - Oncology

  • Inflammatory Diseases

  • Metabolic Diseases

  • Infectious Diseases

  • Cardiovascular Diseases

  • Others

Epigenetics Diagnostics Technology Outlook (Revenue, USD Million, 2018 - 2030) 

• DNA Methylation

  • Reagents

  • Kits

  • Instruments

  • Enzymes

  • Services

• Histone Methylation

  • Reagents

  • Kits

  • Instruments

  • Enzymes

  • Services

• Histone Acetylation

  • Reagents

  • Kits

  • Instruments

  • Enzymes

  • Services

• Large Non - Coding RNA

  • Reagents

  • Kits

  • Instruments

  • Enzymes

  • Services

• MicroRNA Modification

  • Reagents

  • Kits

  • Instruments

  • Enzymes

  • Services

• Chromatin Structures

  • Reagents

  • Kits

  • Instruments

  • Enzymes

  • Services

Epigenetics Diagnostics End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Academic Research

• Clinical Research

• Hospitals & Clinics

• Pharmaceutical & Biotechnology Companies

• Other Users

Epigenetics Diagnostics Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Epigenetics Diagnostics Market

• Hoffmann- La Roche Ltd.

• Thermo Fisher Scientific, Inc.

• Eisai Co. Ltd.

• Novartis AG

• Element Biosciences, Inc.

• Cantata Bio (Dovetail Genomics LLC.)

• Illumina, Inc.

• ValiRx Plc.

• Abcam Ltd.